Heart Failure

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee panel voted 11-4 to support the benefits of the INCRAFT AAA Stent Graft System from Cardinal Health.

Barton-Maxell details the importance of caring for stage A heart failure patients in the primary care setting.

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

Lokelma is approved for the treatment of hyperkalemia, which is characterized by elevated potassium levels often associated with cardiovascular, renal, and metabolic diseases.

The FDA had issued a Class I recall of the MindFrame Capture LP device.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.

Patients who abused substances reported significantly greater cardiovascular and all-cause mortality risk from type 1 MI — despite also reporting lower risks for traditional factors.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

Physical and social improvements were observed in the 8-month visit, but importantly, were sustained in the 3-year follow-up period.

The rate comes in spite of the fact that women are more likely to report more heart attack-associated symptoms, and to have been treated for such symptoms previously, than men.

Depressed elderly patients undergoing SAVR or TAVR had a 7.3% higher rate of mortality compared to non-depressed patients.

Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.

Medtronic’s Azure XT MRI and Azure S MRI pacemakers improved longevity by 27% compared to available predecessors.